Cardiff Oncology, Inc. CRDF
0.82 USD -0.02 (-2.73%)
As ofNov 18, 2026, 11:15 AM EST
0.8126 Day range 0.8617
0.71 52-week range 3.31
- YTD
- -70.70%
- 1 year
- -59.64%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 10.75 +1205.7% upside
Now 0.8233
- Target (low)
- 10.00
- Target (mean)
- 10.75
- Target (high)
- 13.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
Included in Essentials and up
Sign in to see Revenue and earnings forecast
Reported revenue and earnings per share by year, then what analysts expect next.
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.24667 | -0.29 – -0.20 | -0.21 | -17.5% | 73.00K | -53.2% | 3 |
| Next quarter | -0.25 | -0.31 – -0.21 | -0.22 | -13.6% | 76.00K | -62.9% | 3 |
| Current year | -0.98667 | -1.03 – -0.93 | -0.93 | -6.1% | 592.80K | +21.5% | 3 |
| Next year | -1.02 | -1.32 – -0.83 | -0.98667 | -3.0% | 322.00K | -45.7% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Nov 8, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 6, 2024 | Craig-Hallum | Initiated | — | Buy |
| May 6, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 6, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 1, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 11, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 8, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 9, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 29, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 7, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 16, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 13, 2022 | Piper Sandler | Maintained | — | Overweight |
| Aug 29, 2022 | Baird | Maintained | — | Outperform |
| May 9, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Feb 28, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Dec 8, 2021 | Baird | Initiated | — | Outperform |
| Aug 10, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| May 10, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Oct 22, 2020 | HC Wainwright & Co. | Initiated | — | Buy |
| Oct 8, 2020 | Piper Sandler | Initiated | — | Overweight |
| Sep 18, 2020 | Maxim Group | Maintained | — | Buy |
Included in Plus and up
Sign in to see Analyst trend
Two years of the analyst rating mix and the average price target against the price.
